BRIEF-Palatin Completes Enrollment In Phase 2 Clinical Study Of Bremelanotide (MC4R Agonist) Co-Administered With Tirzepatide (GLP-1/GIP) For The Treatment Of Obesity

Reuters10-31

Oct 31 (Reuters) - Palatin Technologies Inc :

* PALATIN COMPLETES ENROLLMENT IN PHASE 2 CLINICAL STUDY OF BREMELANOTIDE (MC4R AGONIST) CO-ADMINISTERED WITH TIRZEPATIDE (GLP-1/GIP) FOR THE TREATMENT OF OBESITY

* PALATIN TECHNOLOGIES INC - TOPLINE RESULTS EXPECTED IN 1Q 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479707102?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479707102","market":"us","top_or_hot":-1,"title":"BRIEF-Palatin Completes Enrollment In Phase 2 Clinical Study Of Bremelanotide (MC4R Agonist) Co-Administered With Tirzepatide (GLP-1/GIP) For The Treatment Of Obesity","media":"Reuters","content":"<html><body><p>Oct 31 (Reuters) - <a href=\"https://laohu8.com/S/PTN\">Palatin Technologies Inc</a>   :</p><p>   * PALATIN COMPLETES ENROLLMENT IN PHASE 2 CLINICAL STUDY OF BREMELANOTIDE (MC4R AGONIST) CO-ADMINISTERED WITH TIRZEPATIDE (GLP-1/GIP) FOR THE TREATMENT OF OBESITY</p><p>   * PALATIN TECHNOLOGIES INC - TOPLINE RESULTS EXPECTED IN 1Q 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Palatin Completes Enrollment In Phase 2 Clinical Study Of Bremelanotide (MC4R Agonist) Co-Administered With Tirzepatide (GLP-1/GIP) For The Treatment Of Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Palatin Completes Enrollment In Phase 2 Clinical Study Of Bremelanotide (MC4R Agonist) Co-Administered With Tirzepatide (GLP-1/GIP) For The Treatment Of Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 19:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 31 (Reuters) - Palatin Technologies Inc   :   * PALATIN COMPLETES ENROLLMENT IN PHASE 2 CLINICAL STUDY OF BREMELANOTIDE (MC4R AGONIST) CO-ADMINISTERED WITH TIRZEPATIDE (GLP-1/GIP) FOR THE ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2479707102","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479707102","pubTimestamp":1730374449,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 31  - Palatin Technologies Inc   :   * PALATIN COMPLETES ENROLLMENT IN PHASE 2 CLINICAL STUDY OF BREMELANOTIDE  CO-ADMINISTERED WITH TIRZEPATIDE  FOR THE TREATMENT OF OBESITY   * PALATIN TECHNOLOGIES INC - TOPLINE RESULTS EXPECTED IN 1Q 2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLP":"全球合伙","PTN":"Palatin Technologies Inc","BK4590":"PTP","BK4144":"石油与天然气的储存和运输"},"translate_title":"BRIEF-Palatin完成Bremelanotide（MC4R激动剂）联合替泽帕肽（GLP-1/GIP）治疗肥胖症的2期临床研究入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1,"PTN":1},"content_text":"Oct 31 (Reuters) - Palatin Technologies Inc   :   * PALATIN COMPLETES ENROLLMENT IN PHASE 2 CLINICAL STUDY OF BREMELANOTIDE (MC4R AGONIST) CO-ADMINISTERED WITH TIRZEPATIDE (GLP-1/GIP) FOR THE TREATMENT OF OBESITY   * PALATIN TECHNOLOGIES INC - TOPLINE RESULTS EXPECTED IN 1Q 2025Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479707102"}